Clinical improvement (non‐recurrence risk) · people with primary or recurrent pterygium
The review found no eligible studies for this question.
1 finding from 1 review
Need for repeat surgery · people with primary or recurrent pterygium
The review found no eligible studies for this question.
1 finding from 1 review
Visual acuity · people with primary or recurrent pterygium
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life · people with primary or recurrent pterygium
The review found no eligible studies for this question.
1 finding from 1 review
Costs (direct and indirect) · people with primary or recurrent pterygium
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Occurrence of ocular involvement · Adult immunocompetent patients with herpes zoster ophthalmicus
It is very uncertain whether the intervention changes occurrence of ocular involvement (very low certainty).
1 finding from 1 review
Intervention not reported
Ocular involvement ‐ Dendritic ulcer · Adult immunocompetent patients with herpes zoster ophthalmicus
It is very uncertain whether the intervention changes ocular involvement ‐ Dendritic ulcer (very low certainty).
1 finding from 1 review
Intervention not reported
Ocular involvement ‐ Uveitis · Adult immunocompetent patients with herpes zoster ophthalmicus
It is very uncertain whether the intervention changes ocular involvement ‐ Uveitis (very low certainty).
1 finding from 1 review
Intervention not reported
Pain at week 24 (self‐reported; yes) · Adult immunocompetent patients with herpes zoster ophthalmicus
It is very uncertain whether the intervention changes pain at week 24 (self‐reported; yes) (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse effects ‐ Vomiting · Adult immunocompetent patients with herpes zoster ophthalmicus
It is very uncertain whether the intervention changes adverse effects ‐ Vomiting (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse effects ‐ Eyelid or facial oedema · Adult immunocompetent patients with herpes zoster ophthalmicus
It is very uncertain whether the intervention changes adverse effects ‐ Eyelid or facial oedema (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse effects ‐ Disseminated zoster · Adult immunocompetent patients with herpes zoster ophthalmicus
It is very uncertain whether the intervention changes adverse effects ‐ Disseminated zoster (very low certainty).
1 finding from 1 review
Intervention not reported
Treatment comparisons · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Acyclovir (B) versus trifluridine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Brivudine (B) versus trifluridine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Brivudine (B) versus acyclovir (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Ganciclovir (B) versus acyclovir (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Low
Intervention not reported
Foscarnet (B) versus trifluridine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Foscarnet (B) versus acyclovir (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Foscarnet (B) versus ganciclovir (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate